How Dual Agonists Work
Dual agonists work on two appetite-regulating hormones simultaneously — GIP and GLP-1. The combination is not merely additive: the two signals interact synergistically, producing greater weight loss than either alone.
Quick read · 4 min
- •Dual agonists activate two hunger signals — GLP-1 and GIP — instead of just one
- •The second signal (GIP) improves how the body handles fat and reduces GI side effects
- •The combination produces more weight loss than GLP-1 drugs alone
- •Tirzepatide is the only approved drug in this class
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026
What GIP is
GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after eating. Like GLP-1, it was originally studied for its role in insulin secretion. More recently, researchers discovered that GIP receptors are also present in the brain, fat tissue, bone, and pancreas — and that activating them has significant effects on appetite and fat metabolism.
How the dual action works
Plain English:
Dual agonists work on two hunger-related signals in the brain instead of one. The second signal (GIP) also improves how the body handles fat and insulin — and because it doesn't trigger as much nausea as GLP-1 at high doses, the two can be combined at full strength. This is why dual agonists tend to produce greater weight loss than single GLP-1 drugs.
- •Reduces appetite via brain receptors
- •Slows gastric emptying
- •Stimulates insulin secretion
- •Suppresses glucagon
- +Additional appetite reduction via brain GIP receptors
- +Improves insulin sensitivity (not just secretion)
- +Enhances fat metabolism via fat cell GIP receptors
- +Mitigates GLP-1's GI side effects
Why GIP matters for tolerability
A key engineering insight behind tirzepatide: GIP activation is well-tolerated at high doses — it does not trigger significant nausea on its own. GLP-1 activation, by contrast, can cause nausea when pushed to high doses.
Tirzepatide is intentionally designed with higher potency at the GIP receptor than at GLP-1. By leading with GIP activation, the molecule can achieve high total receptor engagement (producing significant appetite suppression and weight loss) while limiting nausea compared to equivalent GLP-1 agonism alone. This biased design is part of why tirzepatide showed greater weight loss than semaglutide in the SURMOUNT-5 head-to-head trial.
What the evidence shows
In the SURMOUNT-5 trial (head-to-head vs semaglutide 2.4mg, 72 weeks, 751 adults without diabetes), tirzepatide produced significantly greater weight loss than semaglutide on body weight and waist circumference. This is attributed to the synergistic dual mechanism. Source: NEJM 2025 ↗